Market Place
Sourcing Support
Stock Recap #PipelineProspector
Pipeline Prospector September 2025: Genmab buys Merus for ~US$ 8 billion, Pfizer buys Metsera to enter obesity race
September saw a major clampdown on imports of “branded or patented drugs” into the US, t
Pipeline Prospector August 2025: Novo’s Wegovy approved for MASH, Tonix Pharma’s fibromyalgia drug okayed
In
August, the global pharmaceutical industry witnessed several regulatory
upheavals and policy sh
Pipeline Prospector July 2025: Merck to acquire Verona for US$ 10 bn; FDA okays Regeneron’s blood cancer med
In July, the pharmaceutical industry witnessed several deals and mergers and acquisitions (M&As). Bi
Pipeline Prospector June 2025: Sanofi, AbbVie, Eli Lilly, BioNTech lead pharma M&A spree; BMS, Astra ink major collaborations
In June, the pharmaceutical industry continued to witness more merger and acquisitions, deals, and g
Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals
The month of May saw investors grow increasingly cautious. This resulted in a dip in the biotech ind
Pipeline Prospector April 2025: Merck KGaA buys SpringWorks for US$ 3.9 bn; Swiss giants lead pharma migration to US soil
April witnessed considerable volatility in pharmaceutical stocks as the US President Donald Trump&rs
Pipeline Prospector March 2025: Trump’s FDA overhaul spooks biotech stocks; Roche, AbbVie, Novo ink obesity drug deals
March ended with news that the top vaccine regulator of the US
Food and Drug Administration (FDA),
Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug
February was a mixed bag for biopharma indices, underscoring the volatility and uncertainty in the s
Pipeline Prospector Jan 2025: J&J’s US$ 14.6 bn Intra-Cellular buyout kicks off deal frenzy; Ozempic clinches FDA nod for CKD
January was a busy month that saw several deals being announced at the JP Morgan Healthcare Conferen
Pipeline Prospector 2024 highlights: Rise in new breed of biotechs with maiden approvals; GLP-1 meds show promise beyond obesity
December proved to be one of the most bearish months of 2024 for the biopharma sector. The Nasdaq Bi
Pipeline Prospector Nov 2024: Trump’s HHS pick drags down jab makers’ stocks; Novartis, Merck, Roche ink billion-dollar deals
In November, the markets responded to US President-elect Donald Trump’s picks, particularly th
Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking
In October, several pharma companies posted their third quarter (Q3) results. Drugmakers like Pfizer
Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD
Pharma indices settled slightly lower in September after four months of solid gains. The three major
Pipeline Prospector Aug 2024: Otsuka buys Jnana, Lilly’s market cap gains by over US$ 108 bn post new guidance
As summer draws to a close, pharma and biotech indices posted their fourth consecutive month in the
Pipeline Prospector July 2024: Indices continue to climb; Lilly buys Morphic for US$ 3.2 bn, Kisunla bags FDA nod
The biotechnology sector ended in the green for the third month in a row in July, significantly outp
Pipeline Prospector June 2024: FDA approves Merck’s next-gen pneumococcal vaccine, Verona’s COPD therapy
The pharma indices were back in the black in May, and the good streak continued through June with th
Pipeline Prospector May 2024: J&J inks two deals for eczema drugs; Novo scores trial wins in hemophilia, kidney disease
Pharma indices have rebounded after ending March and April in the red. May saw the Nasdaq Biotechnol
Pipeline Prospector April 2024: Indices dip amid muted Q1 results; Vertex acquires Alpine Immune for US$ 4.9 bn
Pharma indices had begun to recede in March. Their red streak accelerated in April with the Nasdaq B
Pipeline Prospector March 2024: FDA approves pathbreaking NASH drug from Madrigal, two meds for PAH
March was clearly a month of drug approvals, as the US Food and
Drug Administration (FDA) went on a
Pipeline Prospector Feb 2024: Novo’s parent buys Catalent for US$ 16.5 bn, FDA okays Iovance’s cell therapy
February was a good month for the pharma sector, complete with some important deals, successes from
Pipeline Prospector Jan 2024: Vertex’s non-opioid painkiller succeeds in trials; Sanofi buys Inhibrx for US$ 2.2 bn
The New Year got off to a stable start, with some good news
trickling in from clinical trials and B
Pipeline Prospector 2023 highlights: Obesity drugs perk up Lilly, Novo sales; ADCs spur dealmaking
The year 2023 was marked by volatility. The good news is that despite factors like inflation, intere
Pipeline Prospector Nov 2023: Lilly, Novo post sharp rise in Q3 sales; AbbVie buys ImmunoGen for US$ 10.1 billion
Through much of 2023, markets remained volatile, with pharma indices managing to inch up only in som
Pipeline Prospector Oct 2023: Disappointing Q3 results, attacks on Israel, Gaza drag pharma indices down further
October was a gloomy month that saw Palestinian militant group Hamas attack Israel in the first week
Pipeline Prospector Sept 2023: Pharma indices dip further; Merck, BioCardia hit by trial setbacks
Biotech indices underperformed in September. The downward trend witnessed in August got accelerated
Pipeline Prospector Aug 2023: Trial gains, Q2 results push up Lilly, Novo stocks even as indices dip
After a buoyant July, when all the three pharma indices inched up by 2 percent, August proved to be
Pipeline Prospector July 2023: Indices inch up on better than expected Q2 results
July saw all three biotech indices inch up by 2 percent as several drugmakers announced th
Pipeline Prospector June 2023: Lilly, J&J, Merck stocks gain even as indices slip into red
June was a lackluster month for pharma stocks. The Nasdaq Biotechnology Index (NBI) was down 0.7 per
